Stereotaxis revenue misses estimates despite earnings match

Stereotaxis Inc. reported earnings that met market expectations for the latest quarter, but revenue declined year-over-year, missing analyst estimates and weighing on its stock in extended trading.

The medical robotics company, which develops technology for cardiac procedures, said adjusted earnings per share were in line with the consensus forecast. However, total revenue of $14.2 million fell short of the $15.1 million average estimate among analysts polled by Refinitiv, reflecting a 3% decline from the prior-year period.

Gross profit margin expanded to 68.4% from 66.7% a year earlier, as cost controls offset lower sales. The company attributed the revenue shortfall to delayed customer orders and supply chain constraints, which have persisted across the healthcare sector.

Stereotaxis maintained its full-year guidance, reaffirming expectations for revenue between $58 million and $62 million and adjusted EBITDA of $10 million to $12 million. Chief Executive David Fischel highlighted progress in expanding its installed base of robotic systems, though he acknowledged near-term headwinds from macroeconomic pressures.

Shares of Stereotxis were down 4.5% in after-hours trading following the release, extending losses from the regular session where the stock closed at $2.80.